The executive director of Canada’s drug pricing regulator is stepping down—just days after another member resigned because of concerns that the federal government was undermining the regulator’s work. Douglas Clark, executive director of the Patented Medicine Prices Review Board, announced today he will be leaving his post after almost a decade with the regulator. On…

A new Alzheimer’s treatment would cost patients an estimated $26,500 per year, said the drug developer. The Food and Drug Administration (FDA) announced on Jan. 6 that it would grant accelerated approval to Biogen and Eisai, after the drug appeared to partially slow the development of mild cases of Alzheimer’s disease in clinical trials. The same day, Eisai submitted…

OTTAWA—Health Minister Jean-Yves Duclos has put a six-month pause on new regulations designed to lower the cost of patented medicines in Canada. Health Canada first announced the changes in 2019 to protect Canadians from excessive drug prices, but the government has repeatedly delayed implementing the rules. The regulations were supposed to come into force at…